Cargando…

Safety and pharmacokinetics of the Fc-modified HIV-1 human monoclonal antibody VRC01LS: A Phase 1 open-label clinical trial in healthy adults

BACKGROUND: VRC01 is a human broadly neutralizing monoclonal antibody (bnMAb) against the CD4-binding site of the HIV-1 envelope glycoprotein (Env) that is currently being evaluated in a Phase IIb adult HIV-1 prevention efficacy trial. VRC01LS is a modified version of VRC01, designed for extended se...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gaudinski, Martin R., Coates, Emily E., Houser, Katherine V., Chen, Grace L., Yamshchikov, Galina, Saunders, Jamie G., Holman, LaSonji A., Gordon, Ingelise, Plummer, Sarah, Hendel, Cynthia S., Conan-Cibotti, Michelle, Lorenzo, Margarita Gomez, Sitar, Sandra, Carlton, Kevin, Laurencot, Carolyn, Bailer, Robert T., Narpala, Sandeep, McDermott, Adrian B., Namboodiri, Aryan M., Pandey, Janardan P., Schwartz, Richard M., Hu, Zonghui, Koup, Richard A., Capparelli, Edmund, Graham, Barney S., Mascola, John R., Ledgerwood, Julie E.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2018
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5783347/ https://www.ncbi.nlm.nih.gov/pubmed/29364886 http://dx.doi.org/10.1371/journal.pmed.1002493

Ejemplares similares

Phase I Randomized Clinical Trial of VRC DNA and rAd5 HIV-1 Vaccine Delivery by Intramuscular (IM), Subcutaneous (SC) and Intradermal (ID) Administration (VRC 011)
por: Enama, Mary E., et al.
Publicado: (2014)

Phase 1 Study of Pandemic H1 DNA Vaccine in Healthy Adults
por: Crank, Michelle C., et al.
Publicado: (2015)

P14-10. Comparable immunogenicity of VRC DNA and rAd5 HIV-1 vaccines delivered by intramuscular, subcutaneous and intradermal routes in healthy adults (VRC 011)
por: Ledgerwood, JE, et al.
Publicado: (2009)

Safety, tolerability, and immunogenicity of two Zika virus DNA vaccine candidates in healthy adults: randomised, open-label, phase 1 clinical trials
por: Gaudinski, Martin R, et al.
Publicado: (2018)

Safety and Immunogenicity of a rAd35-EnvA Prototype HIV-1 Vaccine in Combination with rAd5-EnvA in Healthy Adults (VRC 012)
por: Crank, Michelle C., et al.
Publicado: (2016)

Safety and Pharmacokinetics of Monoclonal Antibodies VRC07-523LS and PGT121 Administered Subcutaneously for Human Immunodeficiency Virus Prevention
por: Mahomed, Sharana, et al.
Publicado: (2022)

Assessing the safety and pharmacokinetics of the monoclonal antibodies, VRC07-523LS and PGT121 in HIV negative women in South Africa: study protocol for the CAPRISA 012A randomised controlled phase I trial
por: Mahomed, Sharana, et al.
Publicado: (2019)

Extended safety and tolerability of subcutaneous CAP256V2LS and VRC07-523LS in HIV-negative women: study protocol for the randomised, placebo-controlled double-blinded, phase 2 CAPRISA 012C trial
por: Mahomed, Sharana, et al.
Publicado: (2023)

Assessing the safety and pharmacokinetics of the anti-HIV monoclonal antibody CAP256V2LS alone and in combination with VRC07-523LS and PGT121 in South African women: study protocol for the first-in-human CAPRISA 012B phase I clinical trial
por: Mahomed, Sharana, et al.
Publicado: (2020)

A SARS DNA vaccine induces neutralizing antibody and cellular immune responses in healthy adults in a Phase I clinical trial
por: Martin, Julie E., et al.
Publicado: (2008)

DNA priming and influenza vaccine immunogenicity: two phase 1 open label randomised clinical trials
por: Ledgerwood, Julie E, et al.
Publicado: (2011)

Randomized Clinical Trial to Assess the Impact of the Broadly Neutralizing HIV-1 Monoclonal Antibody VRC01 on HIV-1 Persistence in Individuals on Effective ART
por: Riddler, Sharon A, et al.
Publicado: (2018)

An avian influenza H7 DNA priming vaccine is safe and immunogenic in a randomized phase I clinical trial
por: DeZure, Adam D., et al.
Publicado: (2017)

Safety and Immunogenicity of DNA Vaccines Encoding Ebolavirus and Marburgvirus Wild-Type Glycoproteins in a Phase I Clinical Trial
por: Sarwar, Uzma N., et al.
Publicado: (2015)

DNA Vaccine Delivered by a Needle-Free Injection Device Improves Potency of Priming for Antibody and CD8+ T-Cell Responses after rAd5 Boost in a Randomized Clinical Trial
por: Graham, Barney S., et al.
Publicado: (2013)

Structure-guided modification and optimization of antibody VRC07
por: Kwon, Y, et al.
Publicado: (2012)

Genetic variants of IgG1 antibodies and FcγRIIIa receptors influence the magnitude of antibody-dependent cell-mediated cytotoxicity against prostate cancer cells
por: Pandey, Janardan P, et al.
Publicado: (2014)

Partial germline reversions can increase VRC07 potency and breadth
por: Rudicell, RS, et al.
Publicado: (2012)

Safety and immunogenicity of investigational seasonal influenza hemagglutinin DNA vaccine followed by trivalent inactivated vaccine administered intradermally or intramuscularly in healthy adults: An open-label randomized phase 1 clinical trial
por: Carter, Cristina, et al.
Publicado: (2019)

Safety and immunogenicity of an HIV-1 prefusion-stabilized envelope trimer (Trimer 4571) vaccine in healthy adults: A first-in-human open-label, randomized, dose-escalation, phase 1 clinical trial
por: Houser, Katherine V., et al.
Publicado: (2022)

Pharmacokinetics and predicted neutralisation coverage of VRC01 in HIV-uninfected participants of the Antibody Mediated Prevention (AMP) trials
por: Huang, Yunda, et al.
Publicado: (2021)

DNA vaccine priming for seasonal influenza vaccine in children and adolescents 6 to 17 years of age: A phase 1 randomized clinical trial
por: Houser, Katherine V., et al.
Publicado: (2018)

Characterizing the fitness cost of viral escape from the HIV-1 broadly neutralizing monoclonal antibody VRC01
por: Lynch, RM, et al.
Publicado: (2012)

Safety, pharmacokinetics, and immunological activities of multiple intravenous or subcutaneous doses of an anti-HIV monoclonal antibody, VRC01, administered to HIV-uninfected adults: Results of a phase 1 randomized trial
por: Mayer, Kenneth H., et al.
Publicado: (2017)

Prediction of serum HIV-1 neutralization titers of VRC01 in HIV-uninfected Antibody Mediated Prevention (AMP) trial participants
por: Huang, Yunda, et al.
Publicado: (2021)

Modeling cumulative overall prevention efficacy for the VRC01 phase 2b efficacy trials
por: Huang, Yunda, et al.
Publicado: (2018)

Validation of a Triplex Pharmacokinetic Assay for Simultaneous Quantitation of HIV-1 Broadly Neutralizing Antibodies PGT121, PGDM1400, and VRC07-523-LS
por: Wesley, Martina S., et al.
Publicado: (2021)

Neutralizing antibody VRC01 failed to select for HIV-1 mutations upon viral rebound
por: Cale, Evan M., et al.
Publicado: (2020)

DNA Priming for Seasonal Influenza Vaccine: A Phase 1b Double-Blind Randomized Clinical Trial
por: Ledgerwood, Julie E., et al.
Publicado: (2015)

P14-12. Safety and tolerability of VRC DNA and rAd5 HIV-1 vaccine delivery by intramuscular, subcutaneous and intradermal administration in healthy adults
por: Enama, ME, et al.
Publicado: (2009)

Deep sequencing with longitudinal sampling of a VRC01-like-antibody response in a chronically infected individual
por: Zhang, Z, et al.
Publicado: (2012)

Priming Immunization with DNA Augments Immunogenicity of Recombinant Adenoviral Vectors for Both HIV-1 Specific Antibody and T-Cell Responses
por: Koup, Richard A., et al.
Publicado: (2010)

Homologous Boosting with Adenoviral Serotype 5 HIV Vaccine (rAd5) Vector Can Boost Antibody Responses despite Preexisting Vector-Specific Immunity in a Randomized Phase I Clinical Trial
por: Sarwar, Uzma N., et al.
Publicado: (2014)

First-in-human immunoPET imaging of HIV-1 infection using (89)Zr-labeled VRC01 broadly neutralizing antibody
por: Beckford-Vera, Denis R., et al.
Publicado: (2022)

Characteristics of HIV-1 gp120 molecules that bind ancestor, intermediate and mature forms of VRC01-like antibodies
por: Joyce, M, et al.
Publicado: (2012)

Safety and immunogenicity of a ferritin nanoparticle H2 influenza vaccine in healthy adults: a phase 1 trial
por: Houser, Katherine V., et al.
Publicado: (2022)

Pharmacokinetic serum concentrations of VRC01 correlate with prevention of HIV-1 acquisition
por: Seaton, Kelly E., et al.
Publicado: (2023)

Adults on pre-exposure prophylaxis (tenofovir-emtricitabine) have faster clearance of anti-HIV monoclonal antibody VRC01
por: Huang, Yunda, et al.
Publicado: (2023)

Delayed vaginal SHIV infection in VRC01 and anti-α4β7 treated rhesus macaques
por: Calenda, Giulia, et al.
Publicado: (2019)

LHCb LS2 Upgrade
por: Jacobsson, Richard
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_67k88u7nkq2jnqmpr3n7flnu58